N-Octyl-β-valienamine up-regulates activity of F213I mutant β-glucosidase in cultured cells: a potential chemical chaperone therapy for Gaucher disease

[1]  Seiichiro Ogawa,et al.  Chemical chaperone therapy for brain pathology in GM1-gangliosidosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[2]  L. Hou,et al.  [Preclinical research of a new therapy for Gaucher's disease with F213I mutation]. , 2003, Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics.

[3]  I. Wada,et al.  EDEM As an Acceptor of Terminally Misfolded Glycoproteins Released from Calnexin , 2003, Science.

[4]  Ernest Beutler,et al.  Chemical chaperones increase the cellular activity of N370S β-glucosidase: A therapeutic strategy for Gaucher disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[5]  K. Higaki,et al.  Accumulation of cholera toxin and GM1 ganglioside in the early endosome of Niemann–Pick C1-deficient cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Yoshiyuki Suzuki,et al.  Galactonojirimycin derivatives restore mutant human β-galactosidase activities expressed in fibroblasts from enzyme-deficient knockout mouse , 2001, Brain and Development.

[7]  M. Abrahamowicz,et al.  Etiologic determination of childhood developmental delay , 2001, Brain and Development.

[8]  R. Dwek,et al.  Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy , 2001, Journal of Inherited Metabolic Disease.

[9]  Xiaolong Wei,et al.  Hrs Interacts with Sorting Nexin 1 and Regulates Degradation of Epidermal Growth Factor Receptor* , 2001, The Journal of Biological Chemistry.

[10]  C. Scriver,et al.  The Metabolic and Molecular Bases of Inherited Disease, 8th Edition 2001 , 2001, Journal of Inherited Metabolic Disease.

[11]  R. Dwek,et al.  Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis , 2000, The Lancet.

[12]  R. Proia,et al.  Alleviation of neuronal ganglioside storage does not improve the clinical course of the Niemann-Pick C disease mouse. , 2000, Human molecular genetics.

[13]  H. Naim,et al.  Intracellular transport of acid β‐glucosidase and lysosome‐associated membrane proteins is affected in Gaucher's disease (G202R mutation) , 1999 .

[14]  Y. Eto,et al.  Clinical and Molecular Characteristics of Japanese Gaucher Disease , 1999, Neurochemical Research.

[15]  K. Kabayama,et al.  Chemical modification of beta-glucocerebrosidase inhibitor N-octyl-beta-valienamine: synthesis and biological evaluation of N-alkanoyl and N-alkyl derivatives. , 1998, Bioorganic & medicinal chemistry.

[16]  Yoshiyuki Suzuki,et al.  Increased expression of β-hexosaminidase α chain in cultured skin fibroblasts from patients with carbohydrate-deficient glycoprotein syndrome type I , 1998, Brain & development (Tokyo. 1979).

[17]  N. Leslie,et al.  Enzyme therapy for Gaucher disease: the first 5 years. , 1998, Blood reviews.

[18]  J. Dambrosia,et al.  Prospective study of neurological responses to treatment with macrophage‐targeted glucocerebrosidase in patients with type 3 Gaucher's disease , 1997, Annals of neurology.

[19]  C. Prows,et al.  Gaucher disease: enzyme therapy in the acute neuronopathic variant. , 1997, American journal of medical genetics.

[20]  M. Horowitz,et al.  Expression of mutated glucocerebrosidase alleles in human cells. , 1997, Human molecular genetics.

[21]  K. Yamagishi,et al.  Synthesis of potent β-D-glucocerebrosidase inhibitors: N-alkyl-β-valienamines , 1996 .

[22]  J. Dambrosia,et al.  Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase. , 1995, Pediatrics.

[23]  K. Sandhoff,et al.  Sphingolipid activator protein D (sap-D) stimulates the lysosomal degradation of ceramide in vivo. , 1994, Biochemical and biophysical research communications.

[24]  J. Dambrosia,et al.  Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease. , 1991, The New England journal of medicine.

[25]  A. Reuser,et al.  Km mutant of acid α‐glucosidase in a case of cardiomyopathy without signs of skeletal muscle involvement , 1988, Clinical genetics.

[26]  K. Suzuki,et al.  Effect of a heat-stable factor in human placenta on glucosylceramidase, glucosylsphingosine glucosyl hydrolase, and acid beta-glucosidase activities. , 1987, Clinical biochemistry.

[27]  E. Ginns,et al.  Determination of Gaucher's disease phenotypes with monoclonal antibody. , 1983, Clinica chimica acta; international journal of clinical chemistry.

[28]  N. Kondo,et al.  Improvement of neurological symptoms by enzyme replacement therapy for Gaucher disease type IIIb , 2001, European Journal of Pediatrics.

[29]  Satoshi Ishii,et al.  Accelerated transport and maturation of lysosomal α–galactosidase A in Fabry lymphoblasts by an enzyme inhibitor , 1999, Nature Medicine.